QuidelOrtho
QDEL | NASDAQ
$10.21
-$0.53 (-4.93%)
At close: Nov 16, 2026, 4:00 PM ET
$10.19
-$0.02 (-0.20%)
After-hours:
Nov 16, 2026, 7:30 PM ET
QuidelOrtho Company Profile
Company profile explainedCompany Profile
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Key Executives
| Name | Position |
|---|---|
| Brian J. Blaser | President, Chief Executive Officer & Director |
| Jonathan Siegrist | Executive Vice President of Research & Development and Chief Technology Officer |
| Micah Young | Chief Financial Officer & Principal Financial Officer |
| Nathaniel Sisitsky | Chief Legal Officer & Corporate Secretary |
| Bryan Hanson | Executive VP of Global Portfolio Management and Marketing |
| Erich Wolff | Executive Vice President of Strategy & Corporate Development |
| Juliet C. Cunningham | Vice President of Investor Relations |
| Lisa S. Hayes | Vice President of Global Marketing & Corporate Communications |
| Philip McLellan | Chief Operations Officer |
| Ronald Lee Bowman | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 19, 2026 | 4 | Filing |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
QuidelOrtho
| Country | United States |
| IPO Date | Feb 1, 1991 |
| Industry | Medical - Specialties |
| Sector | Healthcare |
| Employees | 6,500 |
| CEO | Brian J. Blaser |
Contact Details
9975 Summers Ridge Road San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | QDEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001906324 |
| CUSIP Number | 219798105 |
| ISIN Number | US2197981051 |
| SIC Code | 2835 |
Recent News
- 3 months ago / prnewswire.comFaster Answers, Better Decisions: ADLM 2026 Highlights
- 3 months ago / seekingalpha.comQuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
- 3 months ago / marketbeat.comQuidelOrtho Q2 Earnings Call Highlights
- 3 months ago / zacks.comQuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
- 3 months ago / prnewswire.comQuidelOrtho Reports Second Quarter 2026 Financial Results
- 3 months ago / zacks.comImplied Volatility Surging for QuidelOrtho Stock Options
- 4 months ago / prnewswire.comQuidelOrtho to Report Second Quarter 2026 Financial Results
- 4 months ago / zacks.comReasons to Add QuidelOrtho Stock in Your Portfolio for Now
- 4 months ago / prnewswire.comBeyond Fentanyl: How the Drug Crisis Is Changing
- 4 months ago / businesswire.comKaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
Add to Watchlist
Select watchlists to add or remove QDEL